VBLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VBLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Vascular Biogenics's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Vascular Biogenics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Vascular Biogenics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Vascular Biogenics's E10 for the quarter that ended in Jun. 2023 is calculated as:
For example, Vascular Biogenics's adjusted earnings per share data for the three months ended in Jun. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Jun. 2023 (Change) | * | Current CPI (Jun. 2023) |
= | -0.01 | / | 128.7287 | * | 128.7287 | |
= | -0.010 |
Current CPI (Jun. 2023) = 128.7287.
Vascular Biogenics Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201309 | -0.379 | 98.790 | -0.494 |
201312 | -0.449 | 98.326 | -0.588 |
201403 | -0.419 | 99.695 | -0.541 |
201406 | -0.200 | 100.560 | -0.256 |
201409 | -2.450 | 100.428 | -3.140 |
201412 | -0.258 | 99.070 | -0.335 |
201503 | -0.150 | 99.621 | -0.194 |
201506 | -0.150 | 100.684 | -0.192 |
201509 | -0.290 | 100.392 | -0.372 |
201512 | -0.140 | 99.792 | -0.181 |
201603 | -0.210 | 100.470 | -0.269 |
201606 | -0.140 | 101.688 | -0.177 |
201609 | -0.120 | 101.861 | -0.152 |
201612 | -0.180 | 101.863 | -0.227 |
201703 | -0.190 | 102.862 | -0.238 |
201706 | -0.180 | 103.349 | -0.224 |
201709 | -0.240 | 104.136 | -0.297 |
201712 | 0.240 | 104.011 | 0.297 |
201803 | -0.240 | 105.290 | -0.293 |
201806 | -0.130 | 106.317 | -0.157 |
201809 | -0.150 | 106.507 | -0.181 |
201812 | -0.100 | 105.998 | -0.121 |
201903 | -0.120 | 107.251 | -0.144 |
201906 | -0.130 | 108.070 | -0.155 |
201909 | -0.140 | 108.329 | -0.166 |
201912 | -0.160 | 108.420 | -0.190 |
202003 | -0.150 | 108.902 | -0.177 |
202006 | -0.140 | 108.767 | -0.166 |
202009 | -0.120 | 109.815 | -0.141 |
202012 | -0.150 | 109.897 | -0.176 |
202103 | -0.120 | 111.754 | -0.138 |
202106 | -0.120 | 114.631 | -0.135 |
202109 | -0.090 | 115.734 | -0.100 |
202112 | -0.120 | 117.630 | -0.131 |
202203 | -0.130 | 121.301 | -0.138 |
202206 | -0.120 | 125.017 | -0.124 |
202209 | -0.120 | 125.227 | -0.123 |
202212 | -0.050 | 125.222 | -0.051 |
202303 | -0.030 | 127.348 | -0.030 |
202306 | -0.010 | 128.729 | -0.010 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Vascular Biogenics (NAS:VBLT) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Vascular Biogenics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Builders Vc Fund I, L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
James Jimin Kim | 10 percent owner | C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404 |
B Capital Group Management, L.p. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
B Capital Group Investors Ii Ltd. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
B Capital Group Partners Ii, L.p. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
Joseph P Wagner | officer: Chief Scientific Officer | 320 HATCH DRIVE, FOSTER CITY CA 94404 |
Tuomo Patsi | director | 320 HATCH DRIVE, FOSTER CITY NY 94404 |
Thomas Bock | director, officer: Chief Executive Officer | 320 HATCH DRIVE, FOSTER CITY NY 94404 |
Michele Galen | director | 320 HATCH DRIVE, FOSTER CITY CA 94404 |
Fr Capital Holdings, L.p. | 10 percent owner | 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103 |
B Capital Fund Ii, L.p. | 10 percent owner | C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
Builders Vc Fund I (canada), L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
Builders Vc Entrepreneurs Fund I, L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
Dubin Thomas I H | director | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Peter Feinberg | director | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-09-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By Business Wire Business Wire • 02-23-2023
By GuruFocusNews GuruFocusNews • 06-06-2022
By GuruFocusNews GuruFocusNews • 07-10-2022
By sperokesalga sperokesalga • 02-16-2023
By Business Wire Business Wire • 02-27-2023
By GuruFocusNews GuruFocusNews • 06-10-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.